ABIONYX’s Strategic Play to Tame a Rare and Devastating Disease

TOULOUSE, France – September 10, 2026

In the world of biotechnology, the journey from a promising molecule to a life-saving medicine is a marathon run through a minefield of scientific, financial, and regulatory challenges. For ABIONYX Pharma, a French biopharmaceutical company, a recent partnership marks a critical milestone in this marathon. The company is developing CER-001, a potential breakthrough therapy for Lecithin-cholesterol acyltransferase (LCAT) deficiency, an ultra-rare genetic disorder that can lead to kidney failure and vision loss. While the drug has already shown life-altering potential in patients under compassionate use, the path to market requires more than clinical success; it demands proof of industrial-scale safety and purity. ABIONYX has just announced a strategic partnership with TEXCELL, a division of ABL Diagnostics, to navigate one of the most complex hurdles in this process: viral safety validation. This move is not just a technical step; it is a calculated maneuver in the high-stakes strategy of bringing a complex biologic drug to the patients who desperately need it.

The Unseen Gauntlet of Biologic Manufacturing

Unlike conventional small-molecule drugs synthesized from chemicals, biologics like CER-001 are large, complex molecules produced in or derived from living systems, such as cell cultures. This biological origin introduces a unique and critical risk: the potential for viral contamination. Regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) impose a formidable set of requirements to mitigate this risk, outlined in guidelines such as the recently updated ICH Q5A(R2). For a company like ABIONYX, proving that its manufacturing process can consistently remove or inactivate any potential viral threat is a non-negotiable gateway to approval.

This is where the partnership with TEXCELL becomes pivotal. Spun out of the prestigious Institut Pasteur in 1987 to address viral safety concerns, TEXCELL is a recognized global expert in conducting the viral clearance studies that regulators demand. These studies involve intentionally “spiking” samples of the drug at various manufacturing stages with a panel of viruses and then demonstrating that the purification process effectively eliminates them. The goal is to document a robust and reproducible defense against contamination, ensuring every batch of the final product is safe.

“Our partnership with TEXCELL represents a significant step forward in the industrialization of CER-001,” said Cyrille Tupin, Chief Executive Officer of ABIONYX Pharma. “We have selected an internationally recognized platform with expertise in viral safety and biosafety to support us through a strategic phase of our development. This collaboration strengthens our industrial and regulatory dossier and contributes to preparing the next stages of CER-001’s development for the treatment of LCAT deficiency.”

The validation from these studies will define the precise industrial parameters for producing the two GMP (Good Manufacturing Practice) batches required by regulators for a Marketing Authorization Application (MAA), which ABIONYX aims to submit to the EMA by early 2028. It is a meticulous, data-driven process that transforms a promising therapy into a verifiable, industrial-grade medicine.

A Lifeline for a Forgotten Disease

The technical complexities of viral clearance stand in stark contrast to the profound human need driving the development of CER-001. LCAT deficiency, which affects an estimated one in a million people, robs the body of its ability to properly process cholesterol. In its most severe form, this leads to cholesterol deposits clouding the corneas, a breakdown of red blood cells, and, most devastatingly, progressive kidney disease that often culminates in end-stage renal failure and the need for dialysis.

With no approved cure, patients rely on managing symptoms and trying to slow the inevitable organ damage. For this small community, CER-001, a mimetic of “good” HDL cholesterol, represents a glimmer of tangible hope. The drug has already received Orphan Drug Designation from both the FDA and EMA, a status that acknowledges the significant unmet need. More importantly, it has demonstrated remarkable effects in real-world settings. As of this year, eight patients across four European countries have received CER-001 under compassionate use programs. Published case studies are compelling: one patient with rapidly progressing renal failure avoided dialysis after treatment, while another saw a reduction in the lipid deposits clogging their kidneys and a slowing of functional decline.

These individual successes, while not a formal clinical trial, provide a powerful clinical foundation for regulatory submission. The partnership with TEXCELL is the industrial parallel to this clinical promise, ensuring the drug that has shown it can help these patients can also be manufactured with the highest degree of safety for a wider population. It is a crucial bridge between individual compassionate cases and broad market access.

A Strategic Play for Industrial Autonomy

ABIONYX’s decision to partner with a French-based expert like TEXCELL is also a strategic move that reflects a broader trend in the European biotech landscape. By investing in local expertise and shoring up its domestic manufacturing and quality control network, the company is building what it calls “industrial autonomy.” This strategy mitigates the risks of relying on complex, global supply chains and fosters a robust local ecosystem for advanced biomanufacturing. It is a decision that aligns with national initiatives like the France 2030 plan, from which ABIONYX has received support for its work in sepsis.

This industrialization effort is backed by a solid financial strategy. In June, ABIONYX secured up to €33 million in financing, specifically earmarking €9 million for the LCAT deficiency MAA submission. The partnership with TEXCELL is a direct deployment of this capital to de-risk one of the most critical components of that submission. While the company is not yet profitable and its stock has seen volatility, analysts maintain a “Strong Buy” consensus, signaling confidence in the long-term value of CER-001’s potential.

Chalom Sayada, Chief Executive Officer of TEXCELL – ABL Diagnostics, highlighted the importance of this capability. “Through the combined expertise of TEXCELL and ABL Diagnostics, we are providing ABIONYX Pharma with an internationally recognized scientific platform that meets the highest regulatory standards and is capable of supporting innovative biopharmaceutical companies through the most advanced stages of their development.”

The Dual-Pronged Path to Market

The industrial and regulatory groundwork being laid for LCAT deficiency has wider implications for ABIONYX. The company is simultaneously advancing CER-001 as a treatment for sepsis-induced acute kidney injury, a far more common and deadly condition. Promising Phase 2a results showed the drug could remove endotoxins and reduce the inflammatory “cytokine storm” characteristic of sepsis. Following a positive pre-IND meeting with the FDA, the company is now planning a pivotal Phase 2b/3 trial for this indication.

The robust manufacturing process and viral safety dossier being established for the rare disease indication will directly support the development pathway for sepsis. This synergistic approach allows the company to pursue a near-term market opportunity in a rare disease, where the regulatory path can be more streamlined, while building the industrial foundation required for a potential blockbuster application in critical care. By methodically clearing each scientific and regulatory hurdle, ABIONYX is not only moving closer to helping patients with LCAT deficiency but is also building a platform for broader impact in modern medicine.